gbola amusa md cfa head hc research
sale trade et
sale trade et
viral news genet medicin rise pi/ii data
highlight week may may meiragtx buy chardan top pick announc posit
month data phase i/ii trial aav-bas gene therapi gt
data show statistically-signific improv even low dose vg/kg mobil test
retin sensit contrast sensit visual acuiti etdrs-lett median improv versu
untreat eye etdrs-lett median improv children data us
signific posit meira inherit retin diseas ird portfolio neutral provid
updat ignit dmd phase i/ii trial aav-bas gt duchenn muscular
dystrophi dmd patient treat vg/kg shortli thereaft experienc elev
liver transaminas bilirubin level greater normal understand indic hy law case case
us demonstr possibl vg/kg may pose risk hepatotox gensight
biolog neutral report data revers phase trial aav-bas gt
leber hereditari optic neuropathi lhon eye demonstr improv visual acuiti
etdr letter baselin etdr letter nadir similar report previous
revers trial phase rescu trial improv visual acuiti
eye fail significantli separ sham-treat eye
look forward may may may estimate gensight biolog host kol event
new york citi may estimate novarti rate host novarti manag boston
weekli price move vivo genet medicin aav srna mrna vivo gene edit
upcom chardan genet medicin event contact chardan rsvp
june network recept host chardan allanc regen medicin philadelphia
gene express precis deliveri futur aso alcyon call upcom
may unrat announc million strateg equiti invest mri intervent
unrat stock also suppli agreement mri precis neurosurg devic use gt program
news follow april announc gyroscop therapeut merg orbit biomed creat
first fully-integr gt compani clinic manufactur deliveri capabl strongli believ deliveri
emerg import factor success genet medicin particular target
note era genet medicin took time arriv part due host issu associ deliveri
part vector lnp deliveri innov help solv believ next step involv transform
devic innov thu host chardan leadership call alcyon lifesci may
exampl discuss way deliveri improv genet medicin like zolgensma sma therapi aso
develop huntington diseas alcyon develop precis deliveri tool deliveri
tumor publicli announc partnership merck co unrat roch unrat unrat dnatrix
privat amylon privat alcyon breakthrough devic design us fda thecaflex drx
system could lead safer effect treatment diseas like sma huntington diseas
buy data full data scientif forum may amusa
pleas refer import disclosur inform regul analyst certif found page report
meiragtx report result announc aav-bas gt met endpoint month phase
i/ii dose-escal trial
mobil test data demonstr statist signific improv time taken navig maze
straight path across full spectrum light level even vg/ml dose
data also demonstr statist signific improv vg/ml dose retin sensit
contrast sensit visual acuiti meira thu select vg/ml use plan pivot trial
reiter johnson johnson unrat deal collabor equiti stake signal posit upcom
dataset meiragtx particularli x-link retin pigmentosa xlrp achromatopsia
buy leadership call support upsid potenti catalyst may livshit
particip leadership call host chardan may replay call avail
continu see upwardli skew risk-reward dynam note follow takeaway call
 avoid common pitfal fail phase trial recurr high-grad glioma rhgg
 efficaci data phase rhgg studi signal durabl clinic benefit patient
 natur fc regimen may enabl uniqu price model
 activ prepar launch multipl front
 phase design reason conserv assumpt control arm surviv
 patient treat fc rel de-risk safeti
 earli complet phase enrol potenti indic patient/clinician interest
 favor data would signal phase ii/iii trial newly-diagnos glioblastoma ndgbm
downgrad neutral ignit dmd cohort see hy law case may amusa
announc sae phase i/ii ignit dmd studi aav-bas gt
dmd thu reduc pt downgrad buy neutral
convers manag understand seriou advers event sae consist hy law
case us suggest dose deliv may pose risk seriou drug-induc liver toxic
continu believ path market could exist competitor adequ suppli
market sarepta unrat unrat us yet convincingli commun abil provid
full suppli compani aav-bas gt
vblt neutral pt academ collab signal clinician confid may livshit
vbl report result discuss new trial viral vector-bas cancer therapi
expect start glioblastoma gbm colon cancer
interest academ investig suggest least clinician accept explan differ avastin dose
schedul reason globe trial failur presum close review data
strateg industri collabor perhap checkpoint combo set would us provid stronger valid
qure buy pt model huntington diseas opportun may amusa
uniqur could believ en rout valuat base support come year could
best-in-class breakthrough huntington diseas hd franchis uniqur expect make
base gt first gt enter clinic hd upgrad peak forecast
risk-adjust sale pt
 target deep brain structur diseas start
note critic differenti increas likelihood breakthrough success
 targets/sil mhtt level seen therapi
 targets/sil full-length mhtt also toxic exon htt fragment
 non-allele-specif broaden market opportun
 test phase i/ii multicent random double-blind trial enrich sever rapidly-
evolv phenotyp repeat think could provid fast path market
buy mean compani highlight asset may amusa
meiragtx asset capabl featur may johnson johnson unrat pharmaceut
busi review support thesi robust meira platform increas
probabl meira acquisit janssen/j come year
page
highlight provid color around comment present
 list meira program select nme approv file time-frame
 highlight meiragtx artner build intern capabl engin aav regul gene
 note retin diseas entri point gene therapi
 furthermor comment retin gene therapi asset posit first-to-market
genet medicin news may may
unrat report result provid corpor updat may
arct buy report result highlight recent progress may
umrx unrat report result provid program updat may
tng fp unrat receiv fda clearanc ind viral vaccin ovarian cancer may
elevatebio privat launch mm seri incub cell gt compani may
ntgn unrat report result provid pipelin updat may
unrat report result highlight recent progress upcom mileston may
poseida privat receiv fda orphan drug design car-t therapi may
unrat report result provid summari recent develop may
unrat report result provid corpor updat may
neutral announc appoint burk whitman board director may
autl unrat report result highlight recent progress may
unrat announc appoint dr christoph heeri chief medic offic may
buy report result provid corpor updat may
unrat dose patient cohort phase i/ii trial mp iiib may
unrat report resign chief offic kathi yi may
unrat receiv fda track design gt candid pku may
poseida tx privat announc collabor match biotherapi privat may
phio unrat report result provid corpor updat may
unrat receiv recommend fund uk spinraza may
sight fp neutral report data revers phase trial lhon may
fcsc unrat report result highlight recent progress may
buy announc construct new manufactur facil may
unrat report result announc departur presid dr torben straight nissen may
privat announc public preclin data mirna tx epilepsi may
adap unrat announc collabor alpin immun scienc spear cell product may
unrat announc anim health collabor plumblin unrat asf vaccin may
tigem publish data use split intein deliv larg gene use multipl aav vector may
buy announc dose patient phase trial dcr-hbv hbv may
unrat receiv orphan drug design oncolyt viru treat malign glioma may
neutral announc lift clinic hold optic phase trial wamd may
page
adverum announc clinic hold fda place optic phase trial aav-bas gt
wet april lift cohort trial cohort receiv dose vg/
eye lower dose use cohort vg/ey lower plan dose escal
vg/ey
despit lift hold cohort remain partial clinic hold cohort plan
dose vg/ey per manag adverum current plan dose highest level base
robust preliminari anatom respons observ first cohort patient adverum continu work
close fda resolv remain comment
buy dose patient phase trial gangliosidosi may
unrat announc resign bosun hau director may
uwashington publish data use engin cell protect infect may
buy announc public preclin data chikungunya viru may
publish scienc immunolog preclin data mrna-bas immunotherapi
chikungunya viru chikv data support initi phase trial
januari evalu safeti toler deliv via intraven infus healthi adult
announc dose subject trial februari
monoclon antibodi mab isol cell survivor natur chikv infect
sequenc encod mrna molecul deliv proprietari lipid nanoparticl lnp human mab
express biolog signific level infus mice investig evalu
protect capac mrna mous model chikv infect
treatment mrna protect mice arthriti musculoskelet tissu infect lethal
reduc viremia undetect level day post-inocul infus mrna nonhuman primat
nhp achiev biolog signific mean maxim mab concentr g/ml half-lif
day treatment well toler dose rang mg/kg preclin data support use
mrna prevent chikv infect human
compani mention report
page
page
select catalyst genet medicin coverag
figur expect zolgensma approv price anticip broad implic vivo gt space
file ind rett syndrom
provid program updat phase i/ii valen trial crigler-najjar syndrom
zolgensma anticip regulatori decis sma type
select optim dose xlmtm
dcr-phxc initi long-term registr roll-ov studi ph
nsr-rpgr provid follow-up data phase xiriu dose escal studi xlrp
file ind inherit amyotroph later sclerosi
file ind cta pomp diseas
aro-aat initi phase ii/iii studi liver diseas
initi phase i/ii trial autosom recess congenit ichthyosi
complet enrol phase iia studi wet
releas cgmp manufactur phase i/ii studi
initi phase i/ii trial
aav-rpgr prelim dose escal data phase i/ii trial xlrp
 fc report plan interim readout phase trial rhgg
initi trial malign
complet phase i/ii studi dystroph epidermolysi bullosa deb
top-lin phase ii data treat deb patient
complet ind-en studi diseas
dose patient phase studi mp
zolgensma anticip approv eu
lumasiran initi illuminate-b -c phase trial
givosiran complet nda applic file applic ahp
provid updat phase i/ii studi hemophilia
report phase i/ii data
nsr-rpgr provid prelim data expans cohort phase ii/iii trial xlrp
page
select catalyst genet medicin coverag
file ind pomp diseas
inclisiran report top-line data orion studi hypercholesterolemia
initi phase i/ii clinic trial huntington diseas
report dose escal data pi/ii trial achm/xlrp
report preliminari data phase i/ii studi batten diseas
initi phase i/ii trial dmd
submit ema lhon
nsr-rpgr report follow-up data open label dose escal phase xiriu studi
report interim efficaci readout phase oval trial ovarian cancer
xlrp report interim data expans arm phase i/ii trial xlrp
dcr-hbv anticip first interim data clinic trial hbv
provid earli data cohort phase i/ii pioneer trial n- rp
file ind phase ii studi diabet retinopathi dr
present interim data pi/ii studi mp ii pi studi mp
present interim data cohort steroid prophyl pi/ii studi hofh
file ind batten diseas
initi phase trial dystroph epidermolysi bullosa deb
file ind ornithin transcarbamylas over-the-counter defici
provid initi data phase trial gangliosidosi
axo-aav-opmd initi clinic trial opmd phase specifi
report interim phase i/ii data rix nidcr/nih
initi dose phase trial hemophilia
initi phase i/ii trial
initi phase iib studi wet
lumasiran present top-line data illuminate-a phase trial
vutrisiran initi helios-b phase studi cardiomyopathi attr amyloidosi
inclisiran file nda hypercholesterolemia
updat dose escal pi/ii ignit trial dmd
zolgensma complet strong phase trial pre-symptomat sma type
provid updat initi safeti studi hemophilia without inhibitor
 aro-enac file clear cell renal cell carcinoma cystic fibrosi
 fc initi phase ii/iii trial newli diagnos glioblastoma
 fc safeti activ readout phase ib trial met solid tumor
submit ind methylmalon acidemia mma
present preclin data new gt program fabri pomp defici
initi phase i/ii trial sjogren syndrom
file ind initi phase i/ii trial al
file ind initi phase i/ii trial wet
initi phase i/ii studi best diseas
 file ind al huntington diseas program
provid follow-up data piib dose-confirm studi hemb
present top-lin data phase i/iia clinic trial wet
initi pivot trial
 fc report final analysi phase trial rhgg
declar develop candid aml
figur alnylam/mdco meira gtx nightstar solid uniqur expect import data read-out
page
select catalyst outsid genet medicin coverag
initi phase dose escal studi danon diseas
initi phase i/ii trial leukocyt adhes deficiency-i
initi phase trial recess dystroph epidermolysi bullosa
initi phase ii trial multipl tumor type
begin patient dose phase trial
initi pivot phase trial rdeb
dtx provid phase i/ii cohort data ornithin transcarbamylas defici
dtx provid pi/ii cohort data glycogen storag diseas type ia gsdia
valoctocogen roxaparvovec valrox provid pi/ii data updat hem
valrox present full piii top-line data hem
valrox submit bla pend fda feedback hemophilia
begin dose patient investigator-sponsor phase i/ii trial cystinosi
initi phase i/ii trial type gaucher diseas
bmn file ind phenylketonuria pku
initi phase ib trial beta-thalassemia
initi phase ii/iii trial dmd
initi phase studi pyruv kinas defici pkd
initi clinic trial charcot-marie-tooth type
file approv transit clinic trial platform manufactur
initi phase i/ii trial adult phenylketonuria
rituximab report preliminari phase cohort expans data r/r nhl
micro-dystrophin initi pivot trial duchenn muscular dystrophi
hmaxi-k initi phase ii studi overact bladder
initi phase i/ii trial gangliosidosi
micro-dystrophin initi confirmatori trial commerci materi dmd
initi phase trial multipl myeloma
tegsedi expect approv brazil hattr amyloidosi
 anticip data readout phase trial hd
ptc-aadc file bla aromat l-amino acid decarboxylas aadc defici
ptc-fa file ind friedreich ataxia fa enter clinic
sea-bcma report preliminari phase dose escal data r/r mm
lentiglobin initi phase studi sickl cell diseas
figur plan file bla aadc defici
page
corpor report factset chardan note mention stock unrat unless state select public gm compani includ adhera therapeut
benitec biopharma fibrocel buy lysogen oncosec medic oxford biomedica buy vbl neutral
figur select price movement week end may vivo gm perform aav srna mrna ivg
page
week-over-week perform vivo genet medicin aav srna mrna vivo gene edit basketstickerratingccm ptupsideclosechang changemc mm genet medicin cap genet medicin vivo cap genet medicin ex vivo cap gene therapytickerratingccm ptupsideclosechang changemc mm adverum genet therapytickerratingccm ptupsideclosechang changemc mm dicerna gene editingtickerratingccm ptupsideclosechang changemc mm logicbio pharmaceut
vivo genet medicin monthli market cap progress select compani
corpor report factset chardan note although avx acquir continu includ exhibit reflect valu creation sub-sector
figur aav-bas gene therapyend-monthli market cap select compani januari present
figur srna mrna therapyend-monthli market cap select compani januari present
figur vivo gene editingend-monthli market cap select compani januari present
page
cap million aav gt sector market cap cap million srna mrna gt sector market cap cap million vivo gene edit sector market cap
aav-bas gene therapi comp meiragtx uniqur chardan top pick
corpor report factset chardan note mention stock unrat unless otherwis state target market cap unrated/nr name model current market
cap refer partner product avexi novarti compani wet hofh mp mp ii phase i/ii trial
figur select public aav-bas gene therapi companiesw prefer buy buy qure buy greater potenti drive upsid aav gt space
page
targettargetccmphas ofpriceccmccmdil mcpercentccm pt mmof sector mmof sectorhighshareof genet technolog privat aav-bas genetherapi molecular ask estev horama stride tamid
srna mrna therapi comp alnylam top pick
corpor report factset chardan note mention stock unrat unless state target market cap unrated/nr name rgl model current market cap
figur select public srna mrna therapi companiesw prefer buy buy greater potenti drive upsid entir srna mrna space
page
targettargetccmphas ofpriceccmccmdil mcpercentccm pt mmof sector mmof sectorhighshareof profitalnylam privat srna mrna therapi companiesadvirna silense sirnaom somagen sylenti ntech curevac ethri etherna immunotherapi genev scienc strand note adhera benitec pharma silenc addit unrat public compani
vivo gene edit comp see greater upsid potenti intellia toolgen
corpor report factset chardan note mention stock unrat unless otherwis state target market cap unrated/nr name model current market
figur vivo gene editingw broadli expect out-performance crispr sector higher potenti perform buy toolgen buy
page
targettargetccmphas ofpriceccmccmdil mcpercentccm pt mmof sector mmof sectorhighshareof profitcrispr privat vivogen edit companiesbeam egenesi excis exon feldan poseida recombinet
genet medicin therapeut approv posit opinion fda and/or ema
date
date
corpor report fda ema chardan note market author glybera expir due uniqur decis appli renew exclud antisens oligonucleotid figur
figur believ recent increas rate approv posit opinion genet medicin sign sector rapidli emerg
page
genet medicin therapeut receiv fda breakthrough therapi ema prime design
date fda btd
date ema prime
hattr amyloidosi polyneuropathi
corpor report fda ema biopharm insight chardan note ema start grant prime design may fda start grant breakthrough therapi design juli
figur believ disproportion amount btd prime design award genet medicin anoth sign sector rapidli emerg
page
date fda rmat
corpor report fda biopharm insight chardan note list may incomplet sinc exampl compani disclos regulatori design
figur regen medicin advanc therapi design allow compani interact fda earlier clinic test process frequent
prioriti review voucher prv valu prv sold compani compani
date prv sale
ultragenyx undisclos
spark
ultragenyx novarti
biomarin undisclos
price prv
sarepta gilead
unit abbvi
sanofi
knight gilead
biomarin sanofi/regeneron pharmaceut
figur prioriti review voucher prv sold million million
page
date fda rpdd
corpor report fda biopharm insight chardan note list rpdd may incomplet sinc exampl compani disclos regulatori design
figur sinc pediatr diseas design potenti lead prioriti review voucher drug approv hidden sourc valu exist compani
page
date fda ftd
crispr vertex
crispr vertex
rp due mutat exon gene
moder sever local scleroderma
corpor report fda biopharm insight chardan note list may incomplet sinc exampl compani disclos regulatori design
figur track design facilit develop process expedit review drug seriou condit unmet medic need
page
date fda ftd
corpor report fda biopharm insight chardan note list may incomplet sinc exampl compani disclos regulatori design
figur track design facilit develop process expedit review drug seriou condit unmet medic need
page
genet medicin select therapeut receiv btd rmat prime rpdd and/or ftd us eu
corpor report chardan note list may incomplet sinc exampl compani disclos regulatori design
figur us/eu regulatori designationsa number genet medicin product receiv fda/ema design speed regulatori process and/or provid market exclus
page
corpor report chardan note list may incomplet sinc exampl compani disclos regulatori design
figur us/eu regulatori designationsa number genet medicin product receiv fda/ema design speed regulatori process and/or provid market exclus
page
corpor report chardan note list may incomplet sinc exampl compani disclos regulatori design
figur us/eu regulatori designationsa number genet medicin product receiv fda/ema design speed regulatori process and/or provid market exclus
page
corpor report chardan note list may incomplet sinc exampl compani disclos regulatori design
figur us/eu regulatori designationsa number genet medicin product receiv fda/ema design speed regulatori process and/or provid market exclus
page
genet medicin regulatori design btd rmat prime ftd rpdd grant time
corpor report chardan note list may incomplet sinc exampl compani disclos regulatori design ema start grant prime design may
fda start grant breakthrough therapi design btd juli pediatr diseas design rpdd rmat design genet medicin began novemb
figur regulatori design btd rmat prime ftd rpdd grant genet medicin consider increas grant
page
designationsyear design grantedgenet medicin regulatori design ytd btdrmatprimeftdrpdd biotechnolog pharmaceut
